Copyright
©2010 Baishideng.
World J Gastroenterol. Jul 7, 2010; 16(25): 3133-3143
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3133
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3133
Characteristic | FOLFOX6 plus cetuximab (arm A, n = 77) | FOLFIRI plus cetuximab (arm B, n = 74) |
Exposure to cetuximab (Q1-Q3) | ||
Median duration, wk | 28.0 (17-46) | 29.1 (13-46) |
Median number of infusions | 26.0 (14-40) | 26.0 (12-42) |
Relative dose intensity, n (%) | ||
Only initial dose | 4 (5) | 3 (4) |
< 60% | 2 (3) | 3 (4) |
60% to < 80% | 15 (19) | 8 (11) |
80% to < 90% | 21 (27) | 20 (27) |
≥ 90% | 35 (45) | 40 (54) |
Exposure to chemotherapy (Q1-Q3) | ||
Median duration, wk | 25.1 (19-28) | 25.5 (14-28) |
Median number of cycles | 12 (7-12) | 12 (6-12) |
Relative dose intensity, n (%) | ||
Oxaliplatin | ||
No dose | 1 (1) | 74 (100) |
< 60% | 4 (5) | - |
60% to < 80% | 24 (31) | - |
80% to < 90% | 22 (29) | - |
≥ 90% | 26 (34) | - |
Irinotecan | ||
No dose | 77 (100) | 2 (3) |
< 60% | - | 3 (4) |
60% to < 80% | - | 18 (24) |
80% to < 90% | - | 13 (18) |
≥ 90% | - | 38 (51) |
Bolus 5-FU | ||
No dose | 1 (1) | 2 (3) |
< 60% | 1 (1) | 2 (3) |
60% to < 80% | 28 (36) | 19 (26) |
80% to < 90% | 19 (25) | 14 (19) |
≥ 90% | 28 (36) | 37 (50) |
Continuous infusion 5-FU | ||
No dose | 1 (1) | 2 (3) |
< 60% | 1 (1) | 3 (4) |
60% to < 80% | 21 (27) | 14 (19) |
80% to < 90% | 13 (17) | 11 (15) |
≥ 90% | 41 (53) | 44 (59) |
Dose reductions1, n (%) | ||
Cetuximab | 9 (12) | 5 (7) |
Chemotherapy | 25 (32) | 17 (23) |
Treatment delays1, n (%) | ||
Any cetuximab | ||
≥ 3 d | 59 (77) | 47 (64) |
≥ 16 d | 12 (16) | 8 (11) |
Any chemotherapy | ||
≥ 3 d | 59 (77) | 51 (69) |
≥ 14 d | 25 (32) | 15 (20) |
Treatment discontinuation1, n (%) | ||
Cetuximab | 13 (17) | 9 (12) |
Chemotherapy | 9 (12) | 4 (5) |
- Citation: Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143
- URL: https://www.wjgnet.com/1007-9327/full/v16/i25/3133.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i25.3133